Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619096 | 0.94 | ABHD6 (0.61) | ABHD6PIK3CAMTORHDAC1NAMPT | |
| SCHEMBL1010120 | 0.92 | NR1H2 (0.63) | ABHD6PIK3CAMTORHDAC1NAMPT | |
| SCHEMBL15000510 | 0.92 | ESR2 (0.65) | ABHD6PIK3CAMTORHDAC1NAMPT | |
| SCHEMBL3873145 | 0.88 | ABHD6 (0.65) | ABHD6HDAC1NAMPTESR2GPR119 | |
| SCHEMBL38652842 | 0.88 | ABHD6 (0.62) | ABHD6HDAC1NAMPTESR2GPR119 | |
| SCHEMBL383293 | 0.87 | TMEM97 (0.62) | ABHD6HDAC1NAMPTESR2GPR119 | |
| SCHEMBL31070584 | 0.87 | ABHD6 (0.64) | ABHD6HDAC1NAMPTESR2GPR119 | |
| SCHEMBL14959464 | 0.86 | ABHD6 (0.68) | ABHD6SMN1; SMN2AOC3HTR1AADRA2A | |
| SCHEMBL3276974 | 0.85 | ABHD6 (0.50) | ABHD6PIK3CAMTORNAMPTESR2 | |
| SCHEMBL3277422 | 0.85 | ABHD6 (0.50) | ABHD6PIK3CAMTORNAMPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022251343-A2 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-01 | — | — | WO | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | ABHD6 1888/4885PIK3CA 4354/4885MTOR 4266/4885 |
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | ABHD6 3334/4885PIK3CA 2365/4885MTOR 2131/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | ABHD6 1766/4885PIK3CA 4151/4885MTOR 2746/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ABHD6 1888/4885PIK3CA 4354/4885MTOR 4266/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | ABHD6 1888/4885PIK3CA 4354/4885MTOR 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.